Ranbaxy’s Indian API Plant Added to 2012 Consent Decree

Drug Industry Daily
A A
Ranbaxy’s regulatory woes deepened Thursday as the FDA prohibited the drugmaker’s Toansa, India, plant from manufacturing and distributing active pharmaceutical ingredients (APIs) for U.S. products after a poor inspection.

To View This Article:

Login

Subscribe To Drug Industry Daily